Amphastar Pharmaceuticals, Inc.
AMPH
$25.42
$0.763.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 720.74M | 725.71M | 712.81M | 681.49M | 644.52M |
| Total Other Revenue | 1.94M | 4.95M | 19.15M | 42.06M | 68.37M |
| Total Revenue | 722.68M | 730.66M | 731.97M | 723.55M | 712.89M |
| Cost of Revenue | 362.35M | 361.65M | 358.11M | 340.20M | 323.08M |
| Gross Profit | 360.33M | 369.01M | 373.86M | 383.35M | 389.81M |
| SG&A Expenses | 99.27M | 97.34M | 94.52M | 92.90M | 88.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 541.01M | 535.96M | 526.55M | 509.29M | 483.01M |
| Operating Income | 181.67M | 194.70M | 205.42M | 214.26M | 229.89M |
| Income Before Tax | 161.84M | 172.75M | 189.19M | 186.07M | 201.63M |
| Income Tax Expenses | 27.13M | 31.12M | 29.67M | 28.35M | 35.12M |
| Earnings from Continuing Operations | 134.71 | 141.63 | 159.52 | 157.72 | 166.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 134.71M | 141.63M | 159.52M | 157.72M | 166.52M |
| EBIT | 181.67M | 194.70M | 205.42M | 214.26M | 229.89M |
| EBITDA | 236.73M | 248.30M | 258.39M | 266.61M | 281.46M |
| EPS Basic | 2.81 | 2.93 | 3.29 | 3.26 | 3.44 |
| Normalized Basic EPS | 2.11 | 2.23 | 2.44 | 2.40 | 2.60 |
| EPS Diluted | 2.67 | 2.76 | 3.06 | 3.01 | 3.14 |
| Normalized Diluted EPS | 2.01 | 2.10 | 2.27 | 2.22 | 2.38 |
| Average Basic Shares Outstanding | 191.19M | 193.14M | 193.72M | 193.70M | 193.78M |
| Average Diluted Shares Outstanding | 201.19M | 205.11M | 208.23M | 209.94M | 211.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |